Baird Downgrades Cogent (COGT) to Neutral, 'fairly valued around these levels'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Baird Downgrades Cogent (COGT) to Neutral, 'fairly valued around these levels'

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

February 22, 2024 2:30 PM EST

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on:

51% week 12 mean change in Total Symptom Score (TSS), including 70% of patients achieving 50% reduction in TSS at week 12 49% week 12 mean improvement in quality-of-life (McQoL)Safety and tolerability profile generally similar to placebo with no grade 3/4 events; no bleeding, edema or cognitive events; no dose reductions and no... More